In conclusion, our in vitro data suggest that the continuous, long-term androgen deprivation induces downregulation or loss of AR and PSMA expression in prostate cancer cells, which may have significance in the progression toward a more aggressive, metastatic prostate cancer disease-state during androgen deprivation therapy. Here, AR is linked to metastatic prostate carcinoma.